EBT-101

N/A

Report date: 2025/07/30 10:29:11

Base Information

Drug NameEBT-101

Drug Alias NameEBT 101EBT-101

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector

Mechanisms of ActionGene expression modulators

TargetsNot applicable

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTemple University University Of California, Berkeley

China Registration ClassN/A

Develop Information

Active CompaniesExcision BioTherapeutics Inc

Inactive CompaniesUniversity Of California, Berkeley Temple University

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A